TheraRadar

Pharma Intelligence, Simplified

Landscape → Oncology

Endometrial Cancer

366 clinical trials

230 active
/
366 total (since 2015)
107
Phase 1 Active
176 total
137
Phase 2 Active
220 total
32
Phase 3 Active
43 total
4
Phase 4 Active
6 total

Top Sponsors (Industry)

Sorted by active Active Done Failed
AstraZeneca 8 0 0
Merck 4 0 0
Genmab 3 1 3
Xencor, Inc. 2 3 0
NiKang Therapeutics, Inc. 2 0 1
NextCure, Inc. 2 1 0
MacroGenics 2 0 0
Daiichi Sankyo 2 0 0
SystImmune Inc. 2 0 0
Karyopharm Therapeutics Inc 2 0 0
Radiopharm Theranostics, Ltd 2 0 0
Evergreen Therapeutics, Inc. 2 0 0
Regeneron 2 0 0
GV20 Therapeutics 2 0 0
Incyte Corporation 1 2 2
NCT05256225 RECRUITING
Testing the Addition of Herceptin Hylecta or Phesgo to the Usual Chemotherapy for HER2 Positive Endometrial Serous Carcinoma or Carcinosarcoma
National Cancer Institute (NCI) n=360
NCT07198074 RECRUITING
Testing the Addition of an Antiangiogenic Drug (Bevacizumab) to Chemotherapy (Carboplatin and Paclitaxel) Combined With Immunotherapy (Pembrolizumab) for pMMR, TP53 Mutated Endometrial Cancer
National Cancer Institute (NCI) n=255
NCT03914612 ACTIVE NOT RECRUITING
Testing the Addition of the Immunotherapy Drug Pembrolizumab to the Usual Chemotherapy Treatment (Paclitaxel and Carboplatin) in Stage III-IV or Recurrent Endometrial Cancer
National Cancer Institute (NCI) n=813
NCT06952504 RECRUITING
A Study to Compare Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab (MK-3475) Versus Pembrolizumab Alone as Treatment in Participants With Mismatch Repair Proficient Endometrial Cancer (MK-2870-033/TroFuse-033/GOG-3119/ENGOT-en29)
Merck Sharp & Dohme LLC n=1,123
NCT07166094 RECRUITING
Study to Assess the Efficacy and Safety of Rina-S Compared to Treatment of Investigator's Choice in Participants With Endometrial Cancer
Genmab n=544
NCT06989112 RECRUITING
DESTINY-Endometrial01: A Phase III Study of Trastuzumab Deruxtecan Plus Rilvegostomig or Pembrolizumab as First-Line Treatment of HER2-Expressing (IHC 3+/2+), Mismatch Repair Proficient (pMMR) Endometrial Cancer
AstraZeneca n=600
NCT07022483 RECRUITING
Study of Trastuzumab Deruxtecan Versus Standard of Care Chemotherapy for HER2-Expressing (IHC 3+/2+) Endometrial Cancer
Daiichi Sankyo n=710
NCT06340568 RECRUITING
A Clinical Study of the Anti-cancer Effects of an Investigational Therapy or Chemotherapy in Patients With Recurring Uterine Cancer
BioNTech SE n=480
NCT05611931 RECRUITING
Selinexor in Maintenance Therapy After Systemic Therapy for Participants With p53 Wild-Type, Advanced or Recurrent Endometrial Carcinoma
Karyopharm Therapeutics Inc n=276
NCT04073706 RECRUITING
Sentinel Node Biopsy in Endometrial Cancer
Queensland Centre for Gynaecological Cancer n=760
NCT07044336 RECRUITING
Puxitatug Samrotecan (AZD8205) Monotherapy vs Chemotherapy in B7-H4-selected Endometrial Cancer (Bluestar-Endometrial01)
AstraZeneca n=700
NCT06712472 RECRUITING
Randomized Phase III Trial Testing Maintenance Olaparib Versus Observation After Adjuvant Chemoradiation for p53abn Endometrial Cancer
Gustave Roussy, Cancer Campus, Grand Paris n=554
NCT06746116 ACTIVE NOT RECRUITING
A Study to Evaluate the Use of Durvalumab in Combination With Platinum-based Chemotherapy Followed by Durvalumab With Olaparib as First-line Treatment in Advanced or Recurrent Endometrial Cancer in Spain
AstraZeneca n=45
NCT06486441 ACTIVE NOT RECRUITING
Study of Sacituzumab Govitecan Versus Treatment of Physician's Choice in Participants With Endometrial Cancer After Platinum-Based Chemotherapy and Immunotherapy (ASCENT-GYN-01/GOG-3104/ENGOT-en26)
Gilead Sciences n=640
NCT06132958 ACTIVE NOT RECRUITING
Sacituzumab Tirumotecan (MK-2870) in Post Platinum and Post Immunotherapy Endometrial Cancer (MK-2870-005)
Merck Sharp & Dohme LLC n=710
NCT07319429 NOT YET RECRUITING
Refining Fertility-sparing Treatment in Endometrial Carcinoma Based on Molecular Classification
Fudan University n=260
NCT06851663 RECRUITING
Trop2-targeted immunoPET Imaging of Solid Tumors
RenJi Hospital n=400
NCT05077215 NOT YET RECRUITING
Efficacy and Safety of a Repurposed Drug Added to the Combination of Len Plus Pem in Advanced Endometrial Cancer
Evergreen Therapeutics, Inc. n=450
NCT05201547 ACTIVE NOT RECRUITING
Endometrial Cancer Patientes MMR Deficient Comparing Chemotherapy vs Dostarlimab in First Line
ARCAGY/ GINECO GROUP n=260
NCT05316467 RECRUITING
Weight Management Plus Megestrol Acetate in Early-stage Endometrioid Carcinoma
Xiaojun Chen n=89
NCT05078047 RECRUITING
Study Comparing the Standard Administration of IO Versus the Same IO Administered Each 3 Months in Patients in Response After 6 Months of Standard IO
UNICANCER n=646
NCT03555422 ACTIVE NOT RECRUITING
Maintenance with Selinexor/Placebo After Combination Chemotherapy in Participants with Endometrial Cancer [SIENDO]
Karyopharm Therapeutics Inc n=263
NCT06584032 RECRUITING
Study of Fruquintinib Plus Sintilimab for Treatment of Advanced Endometrial Cancer
Hutchmed n=412
NCT05255653 RECRUITING
Refining Adjuvant Treatment in Endometrial Cancer Based on Molecular Features
Leiden University Medical Center n=1,615
NCT06475599 NOT YET RECRUITING
Anlotinib Hydrochloride Capsules Combined With TQB2450 in the Treatment of Endometrial Cancer
Chia Tai Tianqing Pharmaceutical Group Co., Ltd. n=420
NCT03785288 RECRUITING
Vaginal Cuff Brachytherapy Fractionation Study
Kara Romano, MD n=258
NCT05797831 RECRUITING
Study of Navtemadlin as Maintenance Therapy in TP53WT Advanced or Recurrent Endometrial Cancer
Kartos Therapeutics, Inc. n=268
NCT03469674 ACTIVE NOT RECRUITING
PORTEC-4a: Molecular Profile-based Versus Standard Adjuvant Radiotherapy in Endometrial Cancer
Leiden University Medical Center n=550
NCT04789694 RECRUITING
Prehabilitation in Gynaecological Cancer Patients
Charles University, Czech Republic n=64
NCT05524389 NOT YET RECRUITING
Study of Early Stage Endometrial Cancer Based on Molecular Classification and Traditional Risk Stratification to Guide Adjuvant Radiotherapy Decisions
Peking Union Medical College Hospital n=624
NCT05489848 NOT YET RECRUITING
Chemotherapy vs Chemoradiotherapy for Post-operative Endometrial Cancer Patients With P53-mutation
Fudan University n=294
NCT03463252 RECRUITING
Value of LNG-IUS as Fertility-preserving Treatment of EAH and EC
West China Second University Hospital n=224
NCT05454358 TERMINATED
Letrozole as Maintenance Therapy for Post-surgical Endometrial Cancer Patients With NSMP
Fudan University n=12
NCT06007586 COMPLETED
Prevention and Treatment of CINV Caused by TC Regimen in Gynecological Malignant Tumor Patients
Sichuan Cancer Hospital and Research Institute n=143
NCT06321068 TERMINATED
BAT1308 in Combination With Platinum-containing Chemotherapy is Used for the First-line Treatment of Advanced or Recurrent dMMR Endometrial Cancer
Bio-Thera Solutions n=5
NCT04159155 TERMINATED
A Study of Various Treatments in Serous or p53 Abnormal Endometrial Cancer
University Health Network, Toronto n=11
NCT03603184 COMPLETED
Atezolizumab Trial in Endometrial Cancer - AtTEnd
Mario Negri Institute for Pharmacological Research n=549
NCT06732635 COMPLETED
Enhanced Recovery After Surgery (ERAS) for Laparoscopic Hysterectomy at Low Risk Endometrial Cancer
Fundacion para la Formacion e Investigacion Sanitarias de la Region de Murcia n=68
NCT04849858 TERMINATED
Pilot Study of Liposomal Bupivacaine Redosing in Patients Undergoing Major Gynecologic Procedures
University of California, Irvine n=13
NCT04970368 TERMINATED
Comparison of Nodal Staging in Endometrial Cancer
Frederick R. Ueland, M.D. n=38
NCT05712941 WITHDRAWN
Comparison of Letrozole With Lerociclib Versus Letrozole With Placebo Control in Patients With Advanced/Metastatic or Recurrent, Grade 1 or Grade 2 Endometrial Cancer
EQRx International, Inc.
NCT04237090 COMPLETED
Feasibility of a Clinical Trial Comparing the Use of Cetirizine to Replace Diphenhydramine in the Prevention of Reactions Related to Paclitaxel
Ciusss de L'Est de l'Île de Montréal n=27
NCT03285802 COMPLETED
Treatment Plan for an Individual Patient With Recurrent Uterine Papillary Serous Carcinoma (UPSC) With PIK3CA Gene Mutation
Greater Baltimore Medical Center n=1

Data: ClinicalTrials.gov